title: An enzyme immunoassay procedure for cancer antigen 125 evaluated.
abstract: The performance of a new enzyme immunoassay (EIA) procedure (Abbott Labs.) for cancer antigen 125 (CA 125) met or exceeded the manufacturer's claims for all analytical variables examined. Overall correlation with results obtained with a radioimmunoassay (RIA) were good. However, near the decision thresholds typically chosen to define a positive result for ovarian carcinoma, EIA results were 10 to 20 arbitrary units/mL less than the RIA results. At specific decision thresholds, therefore, the sensitivities and specificities of the EIA and RIA procedure differed. Adjusting the decision thresholds gave a similar optimum efficiency for each procedure: EIA, 82.9% (decision threshold, 35 units/mL); RIA, 83.4% (decision threshold, 54 units/mL). Receiver-operating characteristic curves showed that the two procedures' ability to distinguish patients with active ovarian carcinoma from those with disease in remission was the same.
authors.affiliation: Department of Pathology, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis 46202.
authors.forename: K W
authors.initials: KW
authors.lastname: Ryder
authors.forename: T O
authors.initials: TO
authors.lastname: Oei
authors.forename: M T
authors.initials: MT
authors.lastname: Hull
authors.forename: M M
authors.initials: MM
authors.lastname: Sample
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D010051:Ovarian Neoplasms / Q000032:analysis; D011863:Radioimmunoassay
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate